Allianz Asset Management
CPRX

Allianz Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Allianz Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.58M Sell
177,607
-195,382
-52% -$5.77M ﹤0.01% 1370
2026
Q1 		$9.24M Buy
372,989
+6,232
+2% +$148K 0.01% 903
2025
Q4 		$8.56M Sell
366,757
-431,191
-54% -$9.61M 0.01% 914
2025
Q3 		$15.7M Sell
797,948
-239,863
-23% -$4.93M 0.02% 671
2025
Q2 		$22.5M Buy
1,037,811
+343,686
+50% +$8.11M 0.03% 540
2025
Q1 		$16.8M Buy
694,125
+554,674
+398% +$12.5M 0.02% 633
2024
Q4 		$2.91M Buy
139,451
+61,517
+79% +$1.32M ﹤0.01% 1275
2024
Q3 		$1.55M Sell
77,934
-14,457
-16% -$268K ﹤0.01% 1502
2024
Q2 		$1.43M Sell
92,391
-5,589
-6% -$87K ﹤0.01% 1438
2024
Q1 		$1.56M Buy
97,980
+38,846
+66% +$585K ﹤0.01% 1270
2023
Q4 		$994K Hold
59,134
– – ﹤0.01% 1600
2023
Q3 		$691K Sell
59,134
-35,122
-37% -$470K ﹤0.01% 1821
2023
Q2 		$1.27M Sell
94,256
-275,801
-75% -$3.97M ﹤0.01% 1456
2023
Q1 		$6.14M Sell
370,057
-42,778
-10% -$706K 0.01% 892
2022
Q4 		$7.68M Buy
412,835
+21,331
+5% +$328K 0.01% 771
2022
Q3 		$5.02M Sell
391,504
-648,041
-62% -$7.68M 0.01% 884
2022
Q2 		$7.29M Buy
1,039,545
+124,020
+14% +$910K 0.01% 987
2022
Q1 		$7.59M Buy
915,525
+878,795
+2,393% +$6.21M 0.01% 1074
2021
Q4 		$249K Buy
36,730
+799
+2% +$5.25K ﹤0.01% 2421
2021
Q3 		$190K Sell
35,931
-59,035
-62% -$323K ﹤0.01% 2503
2021
Q2 		$546K Buy
+94,966
New +$490K ﹤0.01% 1994
2016
Q1 		– Sell
-820,853
Closed -$2.01M – 2500
2015
Q4 		$2.01M Buy
820,853
+7,507
+0.9% +$21.5K ﹤0.01% 1707
2015
Q3 		$2.44M Buy
813,346
+406,327
+100% +$1.75M ﹤0.01% 1530
2015
Q2 		$1.68M Buy
407,019
+93,496
+30% +$373K ﹤0.01% 1771
2015
Q1 		$1.36M Buy
+313,523
New +$1.13M ﹤0.01% 1687

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Allianz Asset Management's CPRX Position: Q2 2026 in Review

Allianz Asset Management reduced its Catalyst Pharmaceutical (CPRX) stake by 52% in Q2 2026, selling an estimated $5.77M and leaving 177,607 shares worth $5.58M. The position accounts for ﹤0.01% of the portfolio, ranked #1370.

Allianz Asset Management first reported a position in CPRX in Q1 2015 and has held it in 25 quarters since. The position peaked at $22.5M in Q2 2025. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Allianz Asset Management held 177,607 shares of Catalyst Pharmaceutical worth $5.58M as of Q2 2026.
  • Allianz Asset Management sold 195,382 Catalyst Pharmaceutical shares in Q2 2026, an estimated $5.77M.
  • Catalyst Pharmaceutical made up ﹤0.01% of Allianz Asset Management's portfolio in Q2 2026, its #1370 holding.
  • Allianz Asset Management first reported a position in Catalyst Pharmaceutical in Q1 2015 and has held it in 25 quarters since.
  • Allianz Asset Management's Catalyst Pharmaceutical position peaked at $22.5M in Q2 2025.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Allianz Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.